Topic
Topic
The FDA is adding NAION vision-loss warnings to all marketed GLP-1 drugs, including Ozempic, Wegovy and Foundayo. Regulators describe the risk as very low, but causation remains unproven.
Novo Nordisk lifted 2026 sales and profit guidance to -2% to +2%. Third-quarter sales beat estimates, while the Wegovy pill poste…
Novo Nordisk says its experimental CagriSema injection achieved 25% weight loss in women in a late-stage analysis, topping the re…
Novo says patients switching from Wegovy or Zepbound injections to its new pill lost another 8.8 pounds on average in three month…
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but…
